(NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its definitive proxy statement ...

Ford's dividend investment thesis remains compelling, thanks to the healthier balance sheet, the rich cash flows, etc. Click ...